好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The ATN Puzzle: Piecing Together an Alzheimer’s Plasma Panel
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (11:45 AM-12:45 PM)
9-010
To provide an accessible and clinically viable plasma panel to assist physicians with the diagnosis of Alzheimer’s disease (AD).
The ATN framework has been widely utilized for the investigation of AD but has predominantly relied on neuroimaging or CSF measurements which are costly and invasive.  Plasma-based measurements of an ATN panel, however, would provide a more accessible and affordable analytical modality for investigation of AD.
Comprehensive analytical validation of assays on high-throughput clinical auto-analyzers were previously performed for measurements of amyloid-beta (Aβ) 1-42 and Aβ 1-40 (for determination of Aβ42/40), phosphorylated-tau181 (pTau181), and neurofilament light chain (NfL).  To investigate the clinical efficacy of each assay, 200 clinical specimens with Aβ status defined using PET imaging were measured.  Specimens were measured on the validated assays as well as predicate assays utilized in clinical studies.  Additionally, receiver operator characteristic (ROC) analysis was performed on assay results to assess the diagnostic ability of each assay.
Comparison of measurements to predicate assays produced a wide degree of correlations (R between 0.64-0.96) with mean biases ranging from -86.5 to 88.9%.  However, ROC analysis of clinical sample results from validated assays produced an area-under-the-curve (AUC) of 0.941 for Aβ42/40, 0.847 for pTau181, and 0.666 for NfL.  These results are consistent with the understood progression of AD along the ATN continuum.  Despite the relative low AUC, NfL results were found to increase as Mini Mental State Exam scores worsened from mild/negligible (21-30) to moderate scores (11-20, p < 0.0001) and from moderate to severe scores (0-10, p < 0.001).

The clinical utility of the validated ATN panel was found to be appropriate for assisting with diagnosis of AD and is now available for physician use.
Authors/Disclosures
Bradley Collier (Labcorp)
PRESENTER 		Dr. Collier has received personal compensation for serving as an employee of Labcorp. Dr. Collier has stock in Labcorp.
Whitney Brandon (Labcorp) Whitney Brandon has received personal compensation for serving as an employee of Labcorp.
Matthew Chappell (Labcorp) Matthew Chappell has received personal compensation for serving as an employee of Labcorp. Matthew Chappell has stock in Labcorp.
Ayla B. Harris (Labcorp) Mrs. Harris has received personal compensation for serving as an employee of Labcorp. Mrs. Harris has stock in Labcorp.
Tien T. Le (Labcorp) No disclosure on file
Ahmed Chenna, PhD (Monogram Biosciences Inc) Dr. Chenna has received personal compensation for serving as an employee of LabCorp-monogram Biosciences. Dr. Chenna has or had stock in LabCorp.
Youssouf Badal Youssouf Badal has nothing to disclose.
Bryan Lim No disclosure on file
Brandon Yee (Monogram Biosciences/LabCorp) Brandon Yee has received personal compensation for serving as an employee of Labcorp. Brandon Yee has stock in Lacborp.
John Winslow, PhD (Monogram Biosciences Inc., Laboratory Corporation of America) Dr. Winslow has received personal compensation for serving as an employee of Labcorp/Monogram Biosciences. Dr. Winslow has received personal compensation for serving as an employee of Labcorp/Monogram Biosciences. Dr. Winslow has stock in Labcorp. Dr. Winslow has received intellectual property interests from a discovery or technology relating to health care.
Christos J. Petropoulos, PhD (Monogram Biosciences, LabCorp) Dr. Petropoulos has received personal compensation for serving as an employee of Labcorp-Monogram Biosciences. Dr. Petropoulos has stock in Laboratory Corporation of America Holdings. Dr. Petropoulos has received intellectual property interests from a discovery or technology relating to health care.
Deborah Boles Deborah Boles has received personal compensation for serving as an employee of Laboratory Corporation of America. Deborah Boles has stock in Laboratory Corporation of America.
Andre Valcour (Labcorp) Andre Valcour has nothing to disclose.
Russell Grant (labcorp) Russell Grant has received personal compensation for serving as an employee of Labcorp. Russell Grant has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for HepQuant. Russell Grant has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ADLM. Russell Grant has stock in Labcorp.